Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …

The crucial role of CD4+ and CD8+ T cells in shaping and controlling immune responses
during immune disease and cancer development has been well established and used to …

Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types.
Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression …

For many cancer types, the immune system plays an essential role in their development and
growth. Based on these rather novel insights, immunotherapeutic strategies have been …

Tumor-infiltrating immune cells play a key role against cancer. However, malignant cells are
able to evade the immune response and establish a very complex balance in which different …

Simple Summary Over the past decade, cell-based immunotherapy has become a powerful
strategy in solid cancer therapy. Tumor-infiltrating lymphocytes (TILs) are a group of …

Background The immune system interacts with cancer cells in various intricate ways that can
protect the individual from overproliferation of cancer cells; however, these interactions can …

Pancreatic ductal adenocarcinoma (PDAC) is an incurable cancer resistant to traditional
treatments, although a limited number of early-stage patients can undergo radical resection …

Cancer therapy has entered a new era, transitioning from unspecific chemotherapeutic
agents to increasingly specific immune-based therapeutic strategies. Among these, chimeric …

Recent advances in neoantigen research have accelerated the development of tumor
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …